Home Daily Intelligence Tracker
    • Plans Blog Contact
    BURZYNSKI RESEARCH INSTITUTE INC logo
    BZYR

    BURZYNSKI RESEARCH INSTITUTE INC

    MaveScore 22 Low model confidence
    Last Price US$0.00 As of Jul 09, 2026
    Market Cap US$525800.0 Company size context
    7D Performance 0.00% Past 7 days
    1Y Performance N/A Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Nov 30, 2025

    224 days old

    Market price date

    Jul 09, 2026

    3 days old

    Coverage

    13/16

    3 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 22 Low confidence

    Stored data quality

    Freshness and coverage checks

    13/16 Partial or delayed snapshot

    Quality

    10/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    12/25 Mixed

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    0/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    0/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Favors positive earnings, positive cash flow, and lower multiples.
    • Highlights research candidates with supportive 3-month and 6-month price regimes.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin, book value per share.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    BURZYNSKI RESEARCH INSTITUTE INC Overview

    Industry: Biotechnology

    Sector: Healthcare

    Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas. Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic Read More

    BURZYNSKI RESEARCH INSTITUTE INC is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    BURZYNSKI RESEARCH INSTITUTE INC

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jan 13, 2026

    Quarterly result summary

    Latest company-filed earnings material is available for source review.

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    SEC filing Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Oct 14, 2025 SEC filing 10-Q Jul 15, 2025 SEC filing 10-K May 20, 2025 SEC filing 10-Q Jan 13, 2025 SEC filing 10-Q Oct 10, 2024 SEC filing 10-Q Jul 15, 2024 SEC filing 10-K May 29, 2024

    Recent News



    Earnings Per Share

    Score 0.00/5
    BURZYNSKI RESEARCH INSTITUTE INC earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 4.00/5
    BURZYNSKI RESEARCH INSTITUTE INC stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    BURZYNSKI RE... BZYR US$525800
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    BURZYNSKI RESEARCH INSTITUTE INC olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    BURZYNSKI RE... BZYR US$525800
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 1.30/5
    BURZYNSKI RESEARCH INSTITUTE INC registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    BURZYNSKI RE... BZYR US$525800
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    BURZYNSKI RESEARCH INSTITUTE INC logo

    BURZYNSKI RESEARCH INSTITUTE INC

    US$0.00

    US$525800.0

    0.00%

    N/A